CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES TREATMENT
About the Disease
Cryopyrin-Associated Periodic Syndromes (CAPS) are a group of rare, hereditary autoinflammatory disorders. They are inherited in an autosomal dominant pattern, which means that a mutation in 1 copy of the gene is enough to cause the disorder. CAPS are characterized by lifelong recurrent symptoms of rash, fever/chills, joint pain, eye redness/pain, and fatigue. The estimated incidence in the United States is 1 to 2 cases per million people.
About our Patient Care
Our dedicated Care Team works with the physician's office and insurance on a patient's behalf to give our patients more time to focus on their treatment and other important aspects of their lives. We are here to listen, provide counseling on treatment, including side-effect management, and assist with sourcing third-party financial assistance.
As part of treatment, we provide:
Dedicated Care Team
We provide prescribers and patients with a dedicated care team for each of our disease-state programs. This includes a primary pharmacy contact, clinical education, side-effect management, scheduled refill calls, and a direct phone, fax, and email address.
Shipping and Coordination of Care
We provide free overnight delivery of medication and necessary medical supplies and manage care coordination between prescribers, sites of care, nurses, and patients to ensure dispense and drug delivery align with the date and location of service.
Financial Assistance
We identify and assist in enrolling qualified patients into manufacturer financial assistance programs to minimize a potential financial burden to patients.
24/7/365 Access to a Pharmacist
We provide prescribers and patients access to a pharmacist 24/7/365 to ensure patients are always cared for.
Supported Treatments
Click on the specialty drug name below to expand and see more information.
ARCALYST® (rilonacept)
Brand Name | ARCALYST® (riloncept)
Manufacturer | Kiniksa Pharmaceuticals (UK), Ltd.
Route of Administration | Subcutaneous Injection
Approved Indication | ARCALYST (rilonacept) is an interleukin-1 blocker indicated for:
- Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older
- Treatment of Recurrent Pericarditis (RP) and reduction in risk of recurrence in adults and pediatric patients 12 years and older
- Maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing 10 kg or more.
Self-Administration | Yes
Product Website | https://arcalyst.com
ARCALYST is a registered trademark of Regeneron Pharmaceuticals, Inc. and is exclusively licensed by Kiniksa Pharmaceuticals.
Sources:
Kastner DL. Familial Mediterranean fever and other hereditary autoinflammatory diseases. In: Jameson JL, Fauci AS, Kasper DL, et al, eds. Harrison’s Principles of Internal Medicine. 20th ed.: McGraw-Hill Education; 2018:2610-2614.
Kuemmerle-Deschner JB. CAPS — pathogenesis, presentation and treatment of an autoinflammatory disease. Semin Immunopathol. 2015;37(4):377-385.
Autosomal dominant inheritance. National Cancer Institute Dictionary of Genetics Terms. Accessed February 23, 2021. https://www.cancer.gov/publications/dictionaries/genetics-dictionary/def/autosomal-dominant-inheritance
ARCALYST. Package insert. Kiniksa Pharmaceuticals (UK), Ltd.; 2021.